تعداد نشریات | 20 |
تعداد شمارهها | 1,149 |
تعداد مقالات | 10,518 |
تعداد مشاهده مقاله | 45,415,500 |
تعداد دریافت فایل اصل مقاله | 11,291,297 |
Comparison of the Antibody Responses Following Vaccination with AstraZeneca and Sinopharm | ||
Iranian Journal of Immunology | ||
دوره 19، شماره 3، آذر 2022، صفحه 321-329 اصل مقاله (1.09 M) | ||
نوع مقاله: Original Article | ||
شناسه دیجیتال (DOI): 10.22034/iji.2022.94298.2300 | ||
نویسندگان | ||
Enayat Anvari1؛ Atefe Ghamar Talepoor2؛ Mahsa Eshkevar Vakili2؛ Narges Karimi2؛ MohammadReza Ataollahi3؛ Gelareh Najafi1؛ Dieter Kabelitz4؛ Iraj Ahmadi* 1؛ Kurosh Kalantar* 2، 5 | ||
1Department of Physiology, Faculty of Medicine, Ilam University of Medical Sciences, Ilam, Iran | ||
2Department of Immunology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran | ||
3Department of Immunology, School of Medicine, Fasa University of Medical Sciences, Fasa, Iran | ||
4Institute of Immunology, University of Kiel, Kiel, Germany | ||
5Autoimmune Diseases Research Center, Shiraz University of Medical Sciences, Shiraz, Iran | ||
چکیده | ||
Background: Vaccines are the most effective way to prevent Coronavirus 2 severe acute respiratory syndrome (SARS-CoV-2). Objectives: To compare the antibody response of healthy individuals vaccinated with either the AstraZeneca (ChAdOx1 nCoV-19) or the Sinopharm (BBIBP-CorV) vaccine, in those who had no prior infection with SARS-CoV-2. Methods: Thirty seven participants were included, of which 17 were administered the AstraZeneca (ChAdOx1 nCoV-19) vaccine, while 20 were given the Sinopharm (BBIBP-CorV) vaccine. SARS-CoV-2 neutralizing antibody and anti-receptor-binding domain (RBD) IgG levels were checked 4 weeks after giving the first and the second dose of either vaccine using the enzyme-linked immunosorbent assay (ELISA) technique. Results: The AstraZeneca (ChAdOx1 nCoV-19) vaccine exhibited a higher levels of anti-(RBD) IgG compared with the Sinopharm (BBIBP-CorV) in both the first (14.51 μg/ml vs. 1.160 μg/ml) and the second (46.68 μg/ml vs. 11.43 μg/ml) doses. About neutralizing Abs, the titer of the antibody was higher in the AstraZeneca (ChAdOx1 nCoV-19) recipients than in the Sinopharm (BBIBP-CorV) subjects after the first (7.77 μg/ml vs. 1.79 μg/ml, p < 0.0001) and the second dose (10. 36 μg/ml vs. 4.88 μg/ml, p < 0.0001). Conclusions: Recipients vaccinated with two doses of the AstraZeneca (ChAdOx1 nCoV-19) had superior quantitative antibody levels than Sinopharm (BBIBP-CorV)-vaccinated subjects. These data suggest that a booster dose may be needed for the Sinopharm (BBIBP-CorV) recipients, to control the COVID-19 pandemic. | ||
کلیدواژهها | ||
COVID-19؛ Neutralizing Antibody؛ Oxford-AstraZeneca؛ Sinopharm؛ Vaccine | ||
آمار تعداد مشاهده مقاله: 958 تعداد دریافت فایل اصل مقاله: 665 |